论文部分内容阅读
目的:探讨神经胶质瘤肿瘤抑制因子候选区基因1(GLTSCR1)对前列腺癌进展的影响及调控。方法:将前列腺癌细胞系DU145、LNCaP分别分为对照组(sh-NC)，基因抑制组(sh-GLTSCR1)，对照组使用慢病毒转染空白载体质粒，基因抑制组转染携带GLTSCR1短发卡RNA(shRNA)的质粒。细胞计数试剂盒(CCK-8)法检测吸光度(n A)值评估细胞增殖能力，划痕实验检测细胞迁移能力。最后使用DU145细胞株在裸鼠皮下接种检测肿瘤大小、重量。采用n t检验评估两组间差异。n 结果:在24、48、72 h时DU145-sh-GLTSCR1组n A值低于对照组[(1.223±0.015、2.142±0.018、2.576±0.036)比(1.754±0.009、2.307±0.001、2.641±0.016)，n t＝51.360，n P<0.001；n t＝15.590，n P<0.001；n t＝2.868，n P<0.05]，差异均有统计学意义；LNCaP-sh-GLTSCR1组n A值低于对照组[(0.322±0.002、0.480±0.003、1.175±0.003)比(0.359±0.001、0.655±0.014、1.473±0.022)，n t＝15.480、12.060、13.600，n P<0.05]，差异均有统计学意义。划痕实验结果显示DU145-sh-GLTSCR1组细胞24 h的愈合程度低于对照组[(0.446±0.030)比(0.543±0.053)，n t＝3.915，n P<0.01]，差异有统计学意义。LNCaP-sh-GLTSCR1组细胞72 h的愈合程度低于对照组[(0.410±0.060)比(0.583±0.083)，n t＝2.927，n P<0.05]，差异有统计学意义。小鼠皮下成瘤模型表明，敲低GLTSCR1组肿瘤重量低于对照组[(0.033±0.012) g比(0.083±0.022) g，n t＝1.987，n P<0.05]，差异有统计学意义。n 结论:GLTSCR1可促进前列腺癌细胞增殖及迁移。“,”Objective:To investigate the effect of glioma tumor suppressor candidate region gene 1 (GLTSCR1) on the progression of prostate cancer.Methods:DU145 and LNCaP cells were transfected with blank vectoror or short hairpin RNA (shRNA) of GLTSCR1. Proliferation was detected by cell count kit, migration was detected by wound-scratch assays, and the effect of GLTSCR1 on prostate cancer n in vivo was detected through cell derived xenograft (CDX) model with DU145. n T test was used to evaluate the difference between the two groups.n Results:The proliferation of DU145 cells [absorbance (n A), (1.223±0.015, 2.142±0.018, 2.576±0.036) vs. (1.754±0.009, 2.307±0.001, 2.641±0.016), n t=51.360, n P<0.05;n t=15.590, n P<0.05;n t=2.868, n P<0.05] and LNCaP cells [n A: (0.3221±0.002, 0.480±0.003, 1.175±0.003) vs. (0.359±0.001, 0.655±0.014, 1.473±0.022), n t=15.480, 12.060, 13.600, all n P<0.01] was suppressed in sh-GLTSCR1 group at 24, 48 and 72 h. The migration index in DU145-sh-GLTSCR1 group [(0.446±0.030) vs. (0.543±0.053),n t=3.915, n P<0.01] and LNCaP-sh-GLTSCR1 group [(0.410±0.060) vs. (0.583±0.083),n t=2.927, n P<0.05] was lower than in control group. CDX model suggested that the tumor burden in the sh-GLTSCR1 group was lower than in control group [(0.033±0.012) g vs. (0.083±0.022) g,n t=1.987, n P<0.05].n Conclusion:GLTSCR1 enhances the proliferation and migration of prostate cancer.